Soufflé Therapeutics raises $135M Series B to take RNA therapies into the clinic
What's the deal? Soufflé Therapeutics has closed an oversubscribed $135 million Series B, led by Juvia GroupDealroom has a profile for this one. Try Dealroom →. The RNA therapies company will use the money to move its three lead programs into clinical studies and advance its preclinical pipeline.
What's the endgame? Soufflé's product engine, REMEDY (Receptor Mediated Delivery), aims to deliver oligonucleotide therapies to specific cells outside the liver — a long-standing bottleneck in genetic medicine. Its lead program targets striated muscle in facioscapulohumeral muscular dystrophy (FSHD), a disease with no approved disease-modifying therapies.
Two further programs target the phospholamban gene in heart cells to address heart failure, and an undisclosed target for muscle and metabolic disorders.
Who's backing it? The round drew new institutional investors TCG Crossover Management, BB BiotechDealroom has a profile for this one. Try Dealroom →, Fidelity Management & Research Company, and Balyasny Asset ManagementDealroom has a profile for this one. Try Dealroom →. Existing backers Amgen VenturesDealroom has a profile for this one. Try Dealroom →, ARCH Venture Partners, Bessemer Venture Partners, Breyer Capital, Leaps by BayerDealroom has a profile for this one. Try Dealroom →, Temasek, and Vida VenturesDealroom has a profile for this one. Try Dealroom → also joined, among others.
"Patients have waited long enough for real precision from targeted therapies," said Stefan Vitorovic, co-founder and managing director of Juvia Group. Chief executive officer Amir Nashat said the backing supports Soufflé's belief that REMEDY "can make an impact in patients' lives."
The signal: At $135 million, the round sits in the top 5% of all US Series B rounds in health by size, underlining strong investor appetite for cell-specific delivery platforms that could extend RNA medicine well beyond the liver.
Read more: morningstar.com
Image credit: Soufflé Therapeutics
